公开(公告)号：US20100137197A1

公开(公告)日：2010-06-03

申请号：US12666426

申请日：2008-06-23

申请人： Sachin Mittal ,  Hossain Jahansouz ,  Suttilug Sotthivirat

发明人： Sachin Mittal ,  Hossain Jahansouz ,  Suttilug Sotthivirat

IPC分类号： A61K38/12

CPC分类号： A61K38/12 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/12 ,  A61K47/26

摘要： A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.

摘要翻译： 冻干的抗真菌组合物包含有效量的（A）卡泊芬净或其药学上可接受的盐; （B）玻璃化转变温度Tg（s）至少约90℃的一种或多种非还原糖; 和（C）有效提供约5至约7范围内的pH的乙酸盐缓冲液; 其中所述一种或多种非还原性糖与卡泊芬净的重量比在约1.1:1至约10:1的范围内; 该组合物的水分含量为约0.8wt。 ％ 或更少; 并且所述组合物的玻璃化转变温度Tg（c）为至少约55℃。所述冻干组合物在高达并且包括室温的温度下具有良好的储存稳定性。 该组合物可以重构用于预防或治疗真菌感染。

公开(公告)号：US20130023462A1

公开(公告)日：2013-01-24

申请号：US13628592

申请日：2012-09-27

申请人： Sachin Mittal ,  Hossain Jahansouz ,  Sutthilug Sotthivirat

发明人： Sachin Mittal ,  Hossain Jahansouz ,  Sutthilug Sotthivirat

IPC分类号： A61K38/12 ,  A61P31/10

CPC分类号： A61K38/12 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/12 ,  A61K47/26

摘要： A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.

摘要翻译： 冻干的抗真菌组合物包含有效量的（A）卡泊芬净或其药学上可接受的盐; （B）玻璃化转变温度Tg（s）至少约90℃的一种或多种非还原糖; 和（C）有效提供约5至约7范围内的pH的乙酸盐缓冲液; 其中所述一种或多种非还原性糖与卡泊芬净的重量比在约1.1:1至约10:1的范围内; 该组合物的水分含量为约0.8wt。 ％ 或更少; 并且所述组合物的玻璃化转变温度Tg（c）为至少约55℃。所述冻干组合物在高达并且包括室温的温度下具有良好的储存稳定性。 该组合物可以重构用于预防或治疗真菌感染。

公开(公告)号：US11077050B2

公开(公告)日：2021-08-03

申请号：US16496182

申请日：2018-03-19

申请人： MERCK SHARP & DOHME CORP. ,  MERCK SHARP & DOHME B. V. ,  Sachin Mittal ,  Irina Kazakevich ,  Himanshu Bhattacharjee ,  Peter Bakker ,  Luke Schenck ,  David J. Goldfarb ,  Amitava Mitra ,  Donna Carroll ,  Nazia Khawaja

发明人： Sachin Mittal ,  Irina Kazakevich ,  Himanshu Bhattacharjee ,  Peter Bakker ,  Luke Schenck ,  David J. Goldfarb ,  Amitava Mitra ,  Donna Carroll ,  Nazia Khawaja

IPC分类号： A61K31/4439 ,  A61K9/00 ,  A61K47/10 ,  A61K47/22 ,  A61K47/26 ,  A61K47/38 ,  A61K9/10

摘要： The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).

公开(公告)号：US20200289406A1

公开(公告)日：2020-09-17

申请号：US16496182

申请日：2018-03-19

申请人： Sachin MITTAL ,  Irina KAZAKEVICH ,  Himanshu BHATTAQCHARJEE ,  Peter BAKKER ,  Luke J. SCHENCK ,  David J. GOLDFARB ,  Amitava MITRA ,  Donna CARROLL ,  Nazia KHAWAJA ,  MERCK SHARP & DOHME CORP. ,  MERCK SHARP & DOHME B. V.

发明人： Sachin Mittal ,  Irina Kazakevich ,  Himanshu Bhattacharjee ,  Peter Bakker ,  Luke Schenck ,  David J. Goldfarb ,  Amitava Mitra ,  Donna Carroll ,  Nazia Khawaja

IPC分类号： A61K9/00 ,  A61K31/4439 ,  A61K47/26 ,  A61K47/22 ,  A61K47/10 ,  A61K47/38

摘要： The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).

公开(公告)号：US20100216848A1

公开(公告)日：2010-08-26

申请号：US12678783

申请日：2008-10-06

申请人： Andrey V. Peresypkin ,  Sachin Mittal

发明人： Andrey V. Peresypkin ,  Sachin Mittal

IPC分类号： A61K31/4412 ,  A61P3/10 ,  A61P3/04

CPC分类号： C07D213/64 ,  A61K9/0019 ,  A61K31/4412 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44

摘要： A liquid pharmaceutical composition comprising N-[1S,2S]-3-[(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[(5-trifluoromethyl)pyridine-2-yl]oxy}propanamide is disclosed, together with processes of preparing the liquid pharmaceutical composition, preparing a vessel containing the liquid pharmaceutical composition, the use of the composition for treating and preventing diabetes or obesity and a method of treating or preventing diabetes or obesity comprising administration to a patient in need thereof of an effective amount of the liquid pharmaceutical composition.

摘要翻译： 一种液体药物组合物，其包含N- [1S，2S] -3 - [（4-氯苯基）-2-（3-氰基苯基）-1-甲基丙基] -2-甲基-2 - {[（5-三氟甲基） 公开了制备液体药物组合物的方法，制备含有液体药物组合物的血管，使用该组合物治疗和预防糖尿病或肥胖的方法，以及治疗或预防糖尿病的方法或 包括向有需要的患者施用有效量的液体药物组合物。